Singapore markets close in 3 hours 49 minutes

Talaris Therapeutics, Inc. (TALS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.47000.0000 (0.00%)
At close: 04:00PM EST
1.4700 0.00 (0.00%)
After hours: 04:02PM EST

Talaris Therapeutics, Inc.

570 South Preston Street
Louisville, KY 40202
United States
502 398 9250

Full-time employees131

Key executives

NameTitlePayExercisedYear born
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBAPres, CEO, Sec. & Director748.06kN/A1968
Dr. Suzanne T. Ildstad M.D.Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director561.73kN/A1953
Ms. Nancy Krieger M.D.Chief Medical Officer591.31kN/A1967
Ms. Mary Kay FentonCFO & TreasurerN/AN/A1964
Mr. Michael ZdanowskiChief Technology OfficerN/AN/A1967
Ms. Suzanne TollerudVP of Corp. Devel.N/AN/AN/A
Mr. Andrew Clyde FarnsworthChief HR OfficerN/AN/A1959
Mr. Eric GornsteinHead of New Product PlanningN/AN/AN/A
Ms. Farah NatoliHead of Portfolio & Program ManagementN/AN/AN/A
Mr. Colby Suire Ph.D.Head of R&DN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Corporate governance

Talaris Therapeutics, Inc.’s ISS governance QualityScore as of 28 November 2022 is 7. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.